secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2026-09-11T21:15:06+00:00
Accession:  0001193125-26-389400
Event type: litigation
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ACADIA derivative settlement preliminarily approved; governance reforms, $1.5M fees
--------------------------------------------------------------------------------

- Court granted preliminary approval on Aug 24, 2026; final hearing set Jan 13, 2027 in San Diego.
- Settlement requires maintaining corporate governance reforms for at least 4 years; no stockholder cash payments.
- Stockholders' counsel to receive $1.5M in fees; service awards up to $5,000 each, court-approved.
- Derivative claims trace to alleged misstatements on Nuplazid sNDA; FDA CRL in Apr 2021 cut shares >45% and 17%.
- Objections due Dec 23, 2026; claims are derivative, not class action, and release all related demands.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526389400/0001193125-26-389400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526389400/d143428d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-389400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer